192 related articles for article (PubMed ID: 28340451)
1. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Del Re M; Fogli S; Derosa L; Massari F; De Souza P; Crucitta S; Bracarda S; Santini D; Danesi R
Cancer Treat Rev; 2017 Apr; 55():71-82. PubMed ID: 28340451
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy.
Lennep BW; Mack J; Poondru S; Hood E; Looney BD; Williams M; Bianco JJ; Morgans AK
Drug Saf; 2024 Apr; ():. PubMed ID: 38607520
[TBL] [Abstract][Full Text] [Related]
3. Niraparib/abiraterone acetate (Akeega) for prostate cancer.
Med Lett Drugs Ther; 2023 Sep; 65(1684):e146-e147. PubMed ID: 37651303
[No Abstract] [Full Text] [Related]
4. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.
Wisinski KB; Cantu CA; Eickhoff J; Osterby K; Tevaarwerk AJ; Heideman J; Liu G; Wilding G; Johnston S; Kolesar JM
Am J Health Syst Pharm; 2015 Jun; 72(11):958-65. PubMed ID: 25987691
[TBL] [Abstract][Full Text] [Related]
5. [Polymedication and oral antitumour therapies - which drug interactions should be considered?].
Späni SN; Mehra T; Dongre K; Leuppi-Taegtmeyer AB
Ther Umsch; 2023 Oct; 80(8):373-376. PubMed ID: 37971529
[TBL] [Abstract][Full Text] [Related]
6. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
[TBL] [Abstract][Full Text] [Related]
7. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ; Chowdhury S; Loriot Y; Sternberg CN; de Bono JS; Tombal B; Carles J; Flaig TW; Dorff TB; Phung D; Forer D; Noonberg SB; Mansbach H; Beer TM; Higano CS
Clin Genitourin Cancer; 2017 Oct; 15(5):610-617.e3. PubMed ID: 28344102
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
[TBL] [Abstract][Full Text] [Related]
9. Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.
Salem S; Komisarenko M; Timilshina N; Martin L; Grewal R; Alibhai S; Finelli A
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):601-608. PubMed ID: 28395931
[TBL] [Abstract][Full Text] [Related]
10. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
[TBL] [Abstract][Full Text] [Related]
11. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES
Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
Flaig TW; Plets M; Hussain MHA; Agarwal N; Mitsiades N; Deshpande HA; Vaishampayan UN; Thompson IM
JAMA Oncol; 2017 Nov; 3(11):e170231. PubMed ID: 28358937
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Hormonal Therapy in Prostate Cancer.
Berruti A; Dalla Volta A
Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; De Porre P; Kheoh T; Park YC; Todd MB; Chi KN;
N Engl J Med; 2017 Jul; 377(4):352-360. PubMed ID: 28578607
[TBL] [Abstract][Full Text] [Related]
16. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study.
Rocha J; Aprikian AG; Vanhuyse M; Cury FL; Hu J; Prévost N; Dragomir A
CMAJ Open; 2017; 5(1):E265-E272. PubMed ID: 28401143
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
[TBL] [Abstract][Full Text] [Related]
18. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Benoist GE; van Oort IM; Smeenk S; Javad A; Somford DM; Burger DM; Mehra N; van Erp NP
Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
[TBL] [Abstract][Full Text] [Related]
20. Association of Tissue Abiraterone Levels and
Mostaghel EA; Cho E; Zhang A; Alyamani M; Kaipainen A; Green S; Marck BT; Sharifi N; Wright JL; Gulati R; True LD; Loda M; Matsumoto AM; Tamae D; Penning TN; Balk SP; Kantoff PW; Nelson PS; Taplin ME; Montgomery RB
Clin Cancer Res; 2017 Aug; 23(16):4592-4601. PubMed ID: 28389510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
